1-7 of 7
Geoffrey Yarranton
Close
Sort by
Journal Articles

An IHC Screen For EphA3 Positive FFPE Tumors

Darren Locke, PhD, Steven Bernstein, PhD, Frank Lynch, PhD, Koushan Siami-Namini, MD, FCAP, Jackie M. Walling, MBChB, PhD, Thomas Yonker, Geoffrey Yarranton, PhD
Journal: Blood
Blood (2013) 122 (21): 4965.
https://doi.org/10.1182/blood.V122.21.4965.4965
Published: 2013
Journal Articles

Analysis Of EphA3 Expression In Hematologic Malignancies By Quantitative PCR

John Woronicz, PhD, Jorge E. Cortes, MD, Jeffrey L. Jorgensen, MD, PhD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Pramoda Challagundla, Jairo Matthews, Jennifer Ho, Jackie M. Walling, MBChB, PhD, Geoffrey Yarranton, PhD, Naveen Pemmaraju, MD
Journal: Blood
Blood (2013) 122 (21): 4981.
https://doi.org/10.1182/blood.V122.21.4981.4981
Published: 2013
Journal Articles

A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies

Jeffrey E Lancet, MD, Andrew H Wei, MBBS, PhD, Simon TS Durrant, Mark S. Hertzberg, MBBS, PhD, FRACP, FRCPA, Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Ian D Lewis, MB, BS, PhD, Brian Jonas, MD, PhD, Jorge E. Cortes, MD, Geoffrey Yarranton, PhD, Jackie M. Walling, MBChB, PhD
Journal: Blood
Blood (2013) 122 (21): 3838.
https://doi.org/10.1182/blood.V122.21.3838.3838
Published: 2013
Journal Articles

GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia

Eric Padron, Jeffrey S. Painter, Sateesh Kunigal, Adam W. Mailloux, Kathy McGraw, Jessica M. McDaniel, Eunhee Kim, Christopher Bebbington, Mark Baer, Geoffrey Yarranton, Jeffrey Lancet, Rami S. Komrokji, Omar Abdel-Wahab, Alan F. List, Pearlie K. Epling-Burnette
Journal: Blood
Blood (2013) 121 (25): 5068–5077.
https://doi.org/10.1182/blood-2012-10-460170
Published: 2013
Includes: Supplemental data
Journal Articles

Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, MD, Jeffrey S Painter, BS, Adam W Mailloux, PhD, Kathy L. McGraw, Jessica M. McDaniel, BS, Christopher Bebbington, DPhil., Mark Baer, PhD, Geoffrey Yarranton, PhD, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Alan F. List, MD, P.K. Epling-Burnette, PharmD, PhD
Journal: Blood
Blood (2012) 120 (21): 3793.
https://doi.org/10.1182/blood.V120.21.3793.3793
Published: 2012
Journal Articles

A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results

Anne Hagey, M.D., Jeffrey E. Lancet, MD, Varghese Palath, PhD, Andrew H Wei, MBBS, PhD, Martin Lackmann, PhD, Jorge E. Cortes, Andrew Boyd, MD, PhD, Dan Shochat, PhD, Geoffrey Yarranton, PhD, Christopher Bebbington, DPhil., Jonathan A. Leff, MD
Journal: Blood
Blood (2011) 118 (21): 4893.
https://doi.org/10.1182/blood.V118.21.4893.4893
Published: 2011
Journal Articles

A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples

Varghese Palath, PhD, Rohini Vekhande, Mark Baer, PhD, Wendy Ching, PhD, Nenad Tomasevic, PhD, David Martinez, Christina Yi, Swathi Bhaskar, Kenneth Luehrsen, Jason Williams, John Leung, Alan F. List, MD, Ling Zhang, MD, Martin Lackmann, PhD, Andrew Boyd, MD, PhD, Andrew Scott, PhD, Daniela Cilloni, MD, PhD, Geoffrey Yarranton, PhD, Christopher Bebbington, DPhil.
Journal: Blood
Blood (2010) 116 (21): 2897.
https://doi.org/10.1182/blood.V116.21.2897.2897
Published: 2010